These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34667294)

  • 1. Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
    Sehatpour P; Javitt DC; De Baun HM; Carlson M; Beloborodova A; Margolin DH; Carlton MBL; Brice NL; Kantrowitz JT
    Neuropsychopharmacology; 2022 Feb; 47(3):711-718. PubMed ID: 34667294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of glycine on auditory mismatch negativity in schizophrenia.
    Greenwood LM; Leung S; Michie PT; Green A; Nathan PJ; Fitzgerald P; Johnston P; Solowij N; Kulkarni J; Croft RJ
    Schizophr Res; 2018 Jan; 191():61-69. PubMed ID: 28602646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
    Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
    Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactive effects of an N-methyl-d-aspartate receptor antagonist and a nicotinic acetylcholine receptor agonist on mismatch negativity: Implications for schizophrenia.
    Hamilton HK; D'Souza DC; Ford JM; Roach BJ; Kort NS; Ahn KH; Bhakta S; Ranganathan M; Mathalon DH
    Schizophr Res; 2018 Jan; 191():87-94. PubMed ID: 28711472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia.
    Zhou Z; Zhu H; Chen L
    PLoS One; 2013; 8(1):e52186. PubMed ID: 23308105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia.
    Liu Y; Jia LN; Wu H; Jiang W; Wang Q; Wang D; Xiong YB; Ren YP; Ma X; Tang YL
    Psychiatry Res; 2022 May; 311():114484. PubMed ID: 35245745
    [No Abstract]   [Full Text] [Related]  

  • 7. A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers.
    Wienberg M; Glenthoj BY; Jensen KS; Oranje B
    J Psychopharmacol; 2010 Aug; 24(8):1183-92. PubMed ID: 19304862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique contributions of sensory discrimination and gamma synchronization deficits to cognitive, clinical, and psychosocial functional impairments in schizophrenia.
    Koshiyama D; Miyakoshi M; Thomas ML; Joshi YB; Molina JL; Tanaka-Koshiyama K; Sprock J; Braff DL; Swerdlow NR; Light GA
    Schizophr Res; 2021 Feb; 228():280-287. PubMed ID: 33493776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Lee M; Balla A; Sershen H; Sehatpour P; Lakatos P; Javitt DC
    Neuropsychopharmacology; 2018 Feb; 43(3):571-582. PubMed ID: 28816240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.
    Roser P; Haussleiter IS; Chong HJ; Maier C; Kawohl W; Norra C; Juckel G
    Psychopharmacology (Berl); 2011 Dec; 218(4):611-20. PubMed ID: 21590281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
    Sehatpour P; Iosifescu DV; De Baun HM; Shope C; Mayer MR; Gangwisch J; Dias E; Sobeih T; Choo TH; Wall MM; Medalia A; Saperstein AM; Kegeles LS; Girgis RR; Carlson M; Kantrowitz JT
    Biol Psychiatry; 2023 Jul; 94(2):164-173. PubMed ID: 36958998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.
    Lavoie S; Murray MM; Deppen P; Knyazeva MG; Berk M; Boulat O; Bovet P; Bush AI; Conus P; Copolov D; Fornari E; Meuli R; Solida A; Vianin P; Cuénod M; Buclin T; Do KQ
    Neuropsychopharmacology; 2008 Aug; 33(9):2187-99. PubMed ID: 18004285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nicotine and the hallucinating brain: effects on mismatch negativity (MMN) in schizophrenia.
    Fisher DJ; Grant B; Smith DM; Borracci G; Labelle A; Knott VJ
    Psychiatry Res; 2012 Apr; 196(2-3):181-7. PubMed ID: 22425471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch negativity (MMN) to spatial deviants and behavioral spatial discrimination ability in the etiology of auditory verbal hallucinations and thought disorder in schizophrenia.
    Perrin MA; Kantrowitz JT; Silipo G; Dias E; Jabado O; Javitt DC
    Schizophr Res; 2018 Jan; 191():140-147. PubMed ID: 28532686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auditory Mismatch Negativity and P300a Elicited by the "Optimal" Multi-feature Paradigm in Early Schizophrenia.
    Fisher DJ; Campbell DJ; Abriel SC; Ells EML; Rudolph ED; Tibbo PG
    Clin EEG Neurosci; 2018 Jul; 49(4):238-247. PubMed ID: 29502452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of NMDA receptor antagonist memantine on mismatch negativity.
    Korostenskaja M; Nikulin VV; Kicić D; Nikulina AV; Kähkönen S
    Brain Res Bull; 2007 May; 72(4-6):275-83. PubMed ID: 17452287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neural mechanisms of mismatch negativity dysfunction in schizophrenia.
    Lee M; Sehatpour P; Hoptman MJ; Lakatos P; Dias EC; Kantrowitz JT; Martinez AM; Javitt DC
    Mol Psychiatry; 2017 Nov; 22(11):1585-1593. PubMed ID: 28167837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects.
    Leung S; Croft RJ; Baldeweg T; Nathan PJ
    Psychopharmacology (Berl); 2007 Nov; 194(4):443-51. PubMed ID: 17611739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Light GA; Zhang W; Joshi YB; Bhakta S; Talledo JA; Swerdlow NR
    Neuropsychopharmacology; 2017 Dec; 42(13):2633-2639. PubMed ID: 28425497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The right profile: mismatch negativity in schizophrenia with and without auditory hallucinations as measured by a multi-feature paradigm.
    Fisher DJ; Labelle A; Knott VJ
    Clin Neurophysiol; 2008 Apr; 119(4):909-21. PubMed ID: 18261954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.